Clinical Neurology and Neurosurgery
Volume 111, Issue 3 , Pages 282-291 , April 2009

An unusually presenting case of sCJD—The VV1 subtype

  • Kaloyan S. Tanev

      Affiliations

    • Department of Psychiatry, Massachusetts General Hospital, 55 Fruit Street, Warren 1220/Blake 11, Boston, MA 02114, United States
    • Corresponding Author InformationCorresponding author. Tel.: +1 617 726 7511; fax: +1 617 724 9155.
    • ,
  • Mimi Yilma

      Affiliations

    • University of Connecticut Health Center, Farmington, CT, United States

Received 16 November 2007 ,Revised 4 September 2008 ,Accepted 12 September 2008.

References 

  1. Prusiner SB. Novel proteinaceous infectious particles cause scrapie. Science. 1982;216(April (4542)):136–144
  2. Prusiner S. Prions. Proc Natl Acad Sci. 1998;95:13363–13383
  3. Collinge J. Molecular neurology of prion disease. J Neurol Neurosurg Psychiatry. 2005;76:906–919
  4. Parchi P, Giese A, Capellari S, Brown P, Schulz-Schaeffer W, Windl O, et al. Classification of sporadic Creutzfeldt–Jacob disease based on molecular and phenotypic analysis of 300 subjects. Ann Neurol. 1999;46:224–233
  5. Gambetti P, Kong Q, Zou W, Parchi P, Chen S. Sporadic and familial CJD: classification and characterization. Br Med Bull. 2003;66:213–239
  6. Heinemann U, Krasnianski A, Meissner B, Varges D, Kallenberg K, Shulz-Schaeffer WJ, et al. Creutzfeldt–Jakob disease in Germany: a prospective 12-year surveillance. Brain. 2007;130:1350–1359
  7. Heinemann U, Krasnianski A, Meissner B, Gloeckner SF, Kretzschmar HA, Zerr I. Molecular subtype-specific clinical diagnosis of prion diseases. Vet Microbiol. 2007;123(August (14)):328–335[Epub 2007 April 7]
  8. Meissner B, Westner IM, Kallenberg K, Krasnianski A, Bartl M, Varges D, et al. Sporadic Creutzfeldt–Jakob disease: clinical and diagnostic characteristics of the rare VV1 type. Neurology. 2005;65:1544–1550
  9. World Health Organization: report of a WHO consultation on global surveillance, diagnosis and therapy of human transmissible spongiform encephalopathies. Geneva, Switzerland: WHO. February 9–11, 1998. WHO/EMC/ZDI/98.9.
  10. World Health Organization, Weekly epidemiological record 1998, 73, 361–372.
  11. Yen CF, Lin RT, Liu CK, Lee PW, Chen CC, Chang YP. The psychiatric manifestation of Creutzfeldt–Jakob disease. Kaohsiung J Med Sci. 1997;13(April (4)):263–267
  12. Tschampa HJ, Neumann M, Zerr I, Henkel K, Schroter A, Shulz-Scaheffer WJ, et al. Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt–Jakob disease. J Neurol Nerusurg Psychiatry. 2001;71:33–39
  13. Steinhoff BJ, Räcker S, Herrendorf G, Poser S, Grosche S, Zerr I, et al. Accuracy and reiability of periodic sharp wave complexes in Creutzfeldt–Jakob disease. Arch Neurol. 1996;53(162):
  14. Zerr I, Pocchiari M, Collins S, Brandel JP, de Pedro Cuesta J, Knight RS, et al. Analysis of EEG and CSF 14-3-3 proteins as aids to the diagnosis of Creutzfeldt–Jakob disease. Neurology. 2000;26:811–815
  15. Castellani RJ, Colucci M, Xie Z, Zou W, Li C, Parchi P, et al. Sensitivity of 14-3-3 protein test varies in subtypes of sporadic Creutzfeldt–Jacob disease. Neurology. 2004;63:436–442
  16. Kenney K, Hsich G, Brechtel C, Gibbs CJ. The cerebrospinal fluid 14-3-3 assay's diagnostic utility among clinically suspected Creutzfeldt–Jakob disease patients: the NIH experience. Neurol. 2002;58(Suppl 3):A250
  17. Cuadrado-Corrales N, Jiménez-Huete A, Albo C, Hortigüela R, Vega L, Cerrato L, et al. Impact of the clinical context on the 14-3-3 test for the diagnosis of sporadic CJD. BMC Neurol. 2006;6:25
  18. Geschwind MD, Martindale J, Miller D, DeArmond SJ, Uyehara-Lock J, Gaskin D, et al. Challenging the clinical utility of the 14-3-3 protein for the diagnosis of sporadic Creutzfeldt–Jakob disease. Arch Neurol. 2003;60:813
  19. Zerr I, Bodemer M, Gefeller O, Otto M, Poser S, Wiltfang J, et al. Detection of 14-3-3 protein in the cerebrospinal fluid supports the diagnosis of Creutzfeldt–Jakob disease. Ann Neurol. 1998;43:32
  20. Chapman T, McKeel DW, Morris JC. Misleading results with the 14-3-3 assay for the diagnosis of Creutzfeldt–Jakob disease. Neurology. 2000;55:1396
  21. Satoh J, Jurohara K, Yukitake M, Kuroda Y. The 14-3-3 protein detectable in the cerevrospinal fluid of patients with prion-unrelated neurological diseases is expressed constitutively in neurons and glial cells in culture. Eur Neurol. 1999;41:216
  22. Collie DA, Sellar RJ, Zeidler M, Colchester AC, Knight R, Will RG. MRI of Creutzfeldt–Jacob disease: imaging features and recommended MRI protocol. Clin Radiol. 2001;56:726–739
  23. Schröter A, Zerr I, Henkel K, Tschampa HJ, Finkenstaedt M, Poser S. Magnetic resonance imaging in the clinical diagnosis of Creutzfeldt–Jakob disease. Arch Neurol. 2000;57:1751–1757
  24. Henkel K, Zerr I, Hertel A, Gratz KF, Schröter A, Tschampa HJ, et al. Positron emission tomography with [(18)F]FDG in the diagnosis of Creutzfeldt–Jakob disease (CJD). J Neurol. 2002;249(June (6)):699–705
  25. Nakajima M, Yamada T, Kusuhara T, Furukawa H, takahashi M, Yamauchi A, et al. results of quinacrine administration to patients with Creutzfeldt–Jakob disease. Dement. Geriatr. Cogn. Disorders. 2004;17(3):158–163
  26. Kobayashi Y, Hirata K, Tanaka H, Yamada T. Quinacrine administration to a patient with Creutzfeldt–Jakob disease who received a cadaveric dura mater graft—an EEG evaluation. Clin Neurol. 2003;43(July (7)):403–408
  27. Muller WE, Laplanche JL, Ushijima H, Schroder HC. Novel approaches in diagnosis and therapy of Creutzfeldt–Jakob disease. Mech Ageing Dev. 2000;116(July (2–3)):193–218
  28. Dyer O. Research groups fail to reach agreement on protocol for treatment trials for CJD. BMJ. 2004;March (328):603
  29. Dyer O. Family finds hospital willing to give experimental CJD treatment. BMJ. 2003 Jan;8:326
  30. Otto M, Cepek L, Ratzka P, Doehlinger S, Boekhoff I, Wiltfang J, et al. Efficacy of flupirtine on cognitive function in patients with CJD. Neurology. 2004;62:714–718
  31. Collins SJ, Sanchez-Juan P, Masters CL, Klug GM, van Duijn C, Poleggi A, et al. Determinants of diagnostic investigation sensitivities across the clinical spectrum of sporadic Creutzfeldt–Jakob disease. Brain. 2006;129(September (Pt 9)):2278–2287[Epub 2006 July 1]
  32. Worrall BB, Herman ST, Capellari S, Lynch T, Chin S, Gambetti P, et al. Type 1 protease resistant prion protein and valine homozygosity at codon 129 of PRNP identify a subtype of sporadic Creutzfeldt–Jakob disease. J Neurol Neurosurg Psychiatry. 1999;67(November (5)):671–674

PII: S0303-8467(08)00320-X

doi: 10.1016/j.clineuro.2008.09.017

Clinical Neurology and Neurosurgery
Volume 111, Issue 3 , Pages 282-291 , April 2009

Article Tools

* Image Usage & Resolution